IP Library Granted Patent US 7,238,814
Granted Patent B2
US 7,238,814 · App. 10/781,705 · Granted Jul 3, 2007

Compositions of S-nitrosothiols and methods of use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,238,814
App. No.
10/781,705
Granted
Jul 3, 2007
Kind
B2
Abstract

The invention describes compositions and kits comprising 4-aza-4-(2-methyl-2-sulfanylpropyl) tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione; 4-aza-4-(2-methyl-2-(nitrosothio)propyl) tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione; 4-{1-methyl-1-((2,4,6-trimethoxyphenyl)methylthio)ethyl}-1,3-oxazolidin-2-one; 2-aAmino-3-methyl-3-((2,4,6-trimethoxyphenyl)methylthio)butan-1-ol; 4-(1-methyl-1-(nitrosothio)ethyl)-1,3-oxazolidin-2-one; or pharmaceutically acceptable salts thereof. The compositions of the invention can further comprise at least one penetration enhancer, at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one vasoactive agent.

Claims (6)

1. A compound selected from the group consisting of 4-aza-4-(2-methyl-2-(nitrosothio)propyl) tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione or a pharmaceutically acceptable salt thereof; and 4-(1-methyl-1-(nitrosothio)ethyl)-1,3-oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

2. A composition comprising the compound of claim 1 and a pharmaceutically acceptable carrier.

3. A kit comprising at least one compound of claim 1 .

4. A compound selected from the group consisting of 4-aza-4-(2-methyl-2-sulfanylpropyl) tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione or a pharmaceutically acceptable salt thereof; 4-{1-methyl-1-((2,4,6-trimethoxyphenyl)methylthio)ethyl}-1,3-oxazolidin-2-one or a pharmaceutically acceptable salt thereof; and 2-amino-3-methyl-3-((2,4,6-trimethoxyphenyl) methylthio)butan-1-ol or a pharmaceutically acceptable salt thereof.

5. 4-aza-4-(2-methyl-2-(nitrosothio)propyl)tricyclo(5.2.1.0<2,6>)dec-8-ene-3,5-dione or a pharmaceutically acceptable salt thereof.

6. 4-(1-methyl-1-(nitrosothio)ethyl)-1,3-oxazolidin-2-one or a pharmaceutically acceptable salt thereof.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2009
From: NITROMED, INC.
To: NICOX S.A.
Reel/Frame 022846/0320 →